Cutia Therapeutics
2487.HK News Today: Stay Updated with the Latest Cutia Therapeutics News in Real Time
Find 2487.HK news now at Meyka AI. Stay informed with the latest Cutia Therapeutics stocks updates, including price news, market analysis, and expert insights.
Jefferies Maintains Buy for CTMX (CytomX Therapeutics) March 18, 2026
Jefferies maintained Buy on CTMX March 18, 2026. Read CTMX analyst rating, $16 PT, and Meyka AI grade B+
Jefferies Maintains Buy on Protagonist Therapeutics (PTGX) PT $121 Mar 2026
PTGX analyst rating update: Jefferies, Johnson Rice maintain Buy; PT $121 and royalty model cited
CHM.AX gains 100% pre-market on ASX: clinical catalysts and liquidity signal
Pre-market: CHM.AX stock jumps 100% to A$0.002 on ASX. We analyse drivers, valuation and Meyka AI forecast
CHF2.885 intraday (SIX): RLF.SW Relief Therapeutics may test CHF3.20 31 Mar 2026
RLF.SW stock intraday: CHF2.885, oversold bounce setup on SIX. Meyka AI forecast and technical outlook for Relief Therapeutics
ITRM Iterum Therapeutics plc NASDAQ -66% intraday 30 Mar 2026: heavy volume
ITRM stock down 66% intraday on NASDAQ 30 Mar 2026 with huge volume; short-term outlook and Meyka AI forecast compare risks and upside
NITI Aayog March 29: Gut Health Warning Puts Probiotics, Digital Care in Focus
NITI Aayog probiotics warning spotlights gut health, evidence-based products, digital health India, and generic medicines policy. We map investor catalysts, risks, and policy signals for India’s nutri
^DJI Today, March 26: Middle East De-escalation Sparks Best Day Since Feb
Dow Jones today jumps on Middle East de-escalation, marking its best day since February. See drivers of the Dow rally, key levels, and how Australian investors can position into a potential stock mark
BTIG Maintained Buy on Aldeyra Therapeutics (ALDX) March 17, 2026
BTIG maintained Buy on Aldeyra; read our ALDX analyst rating summary and implications
Jefferies Maintains Buy on CytomX Therapeutics, Inc. (CTMX) $16 PT Mar 2026
CTMX analyst rating: Jefferies maintains Buy and raises PT to $16. Read implications and Meyka AI grade B+